L-MTP-PE and zoledronic acid combination in osteosarcoma: Preclinical evidence of positive therapeutic combination for clinical transfer

Osteosarcoma, the most frequent malignant primary bone tumor in pediatric patients is characterized by\ud osteolysis promoting tumor growth. Lung metastasis is the major bad prognosis factor of this disease. Zoledronic\ud Acid (ZA), a potent inhibitor of bone resorption is currently evaluated in phase III randomized studies in Europe for\ud the treatment of osteosarcoma and Ewing sarcoma. The beneicial effect of the liposomal form of Muramyl-TriPeptide-Phosphatidyl\ud Ethanolamine (L-mifamurtide, MEPACT®), an activator of macrophage populations has been demonstrated\ud to eradicate lung metastatic foci in osteosarcoma. The objective of this study was to evaluate the potential\ud therapeutic beneit and the safety of the ZA and L-mifamurtide combination in preclinical models of osteosarcoma,\ud as a prerequisite before translation to patients. The effects of ZA (100 µg/kg) and L-mifamurtide (1 mg/kg) were\ud investigated in vivo in xenogeneic and syngeneic mice models of osteosarcoma, at clinical (tumor proliferation,\ud spontaneous lung metastases development), radiological (bone microarchitecture by microCT analysis), biological\ud and histological levels. No interference between the two drugs could be observed on ZA-induced bone protection\ud and on L-mifamurtide-induced inhibition of lung metastasis development. Unexpectedly, ZA and L-mifamurtide association\ud induced an additional and in some cases synergistic inhibition of primary tumor progression. L-mifamurtide\ud has no effect on tumor proliferation in vitro or in vivo, and macrophage population was not affected at the tumor\ud site whatever the treatment. This study evidenced for the irst time a signiicant inhibition of primary osteosarcoma\ud progression when both drugs are combined. This result constitutes a irst proof-of-principle for clinical application in osteosarcoma patients.\ud